دورية أكاديمية
Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases
| العنوان: | Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases |
|---|---|
| المؤلفون: | Carretero-Barrio, Irene, Caniego-Casas, Tamara, Rosas, Marta, Sánchez, María Concepción, Martínez-Jáñez, Noelia, Chiva, Miguel, Sarrió, David, Moreno-Bueno, Gema, Palacios Calvo, José, Pérez-Mies, Belén |
| المساهمون: | Instituto de Salud Carlos III, European Commission, Centro de Investigación Biomédica en Red Cáncer (España) |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute |
| سنة النشر: | 2023 |
| المجموعة: | Digital.CSIC (Consejo Superior de Investigaciones Científicas / Spanish National Research Council) |
| مصطلحات موضوعية: | Breast carcinoma, HER2, mRNA, Immunohistochemistry |
| الوصف: | Xpert Breast Cancer STRAT4 is a RT-qPCR platform that studies the mRNA expression of ESR1, PGR, MKI67 and ERBB2, providing a positive or negative result for each of these breast cancer biomarkers. Its concordance with immunohistochemistry (IHC) and in situ hybridization (ISH) has been previously demonstrated, but none of the previous works was focused on HER2-equivocal (2+) cases identified by IHC. Thus, we studied the concordance between IHC/ISH and STRAT4 results for 112 HER2 2+ IBC samples, using 148 HER2 0+, 1+ and 3+ (no-HER2 2+) samples for comparison. We found 91.3% accuracy for the determination of HER2 status globally, 99.3% for no-HER2 2+ samples and 80.7% for HER2 2+ samples. Regarding the other biomarkers, we obtained 96.4% accuracy for estrogen receptor, 84.1% for progesterone receptor and 58.2% for Ki67. Our results suggest that the use of ERBB2 mRNA for the evaluation of HER2 2+ cases is not a reliable reflex method to assess the ERBB2 amplification status. ; This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI22/01892” and co-funded by the European Union. Developed with the financial support of Immune4ALL Project (PMP22/00054), with European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII. Funden by CIBERONC (grants CB16/12/00316 and CB16/12/00295) and the European Development Regional Fund “A way to achieve Europe” (FEDER). Cepheid provided material support for this study. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | unknown |
| العلاقة: | Publisher's version; http://dx.doi.org/10.3390/cancers15061688Test; Sí; e-issn: 2072-6694; Cancers 15(6): 1688 (2023); http://hdl.handle.net/10261/340248Test |
| DOI: | 10.3390/cancers15061688 |
| الإتاحة: | https://doi.org/10.3390/cancers15061688Test http://hdl.handle.net/10261/340248Test |
| حقوق: | open |
| رقم الانضمام: | edsbas.C95FF1E8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers15061688 |
|---|